<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and Development&quot; 2018ZX09711003 Dear Editor, In December 2019, a novel" exact="pneumonia" post="caused by a previously unknown pathogen emerged in Wuhan,"/>
 <result pre="a novel coronavirus (2019-nCoV), which is closely related to sever" exact="acute" post="respiratory syndrome CoV (SARS-CoV).2 Currently, there is no specific"/>
 <result pre="novel coronavirus (2019-nCoV), which is closely related to sever acute" exact="respiratory" post="syndrome CoV (SARS-CoV).2 Currently, there is no specific treatment"/>
 <result pre="coronavirus (2019-nCoV), which is closely related to sever acute respiratory" exact="syndrome" post="CoV (SARS-CoV).2 Currently, there is no specific treatment against"/>
 <result pre="new virus. Therefore, identifying effective antiviral agents to combat the" exact="disease" post="is urgently needed. An efficient approach to drug discovery"/>
 <result pre="whether the existing antiviral drugs are effective in treating related" exact="viral" post="infections. The 2019-nCoV belongs to Betacoronavirus which also contains"/>
 <result pre="belongs to Betacoronavirus which also contains SARS-CoV and Middle East" exact="respiratory" post="syndrome CoV (MERS-CoV). Several drugs, such as ribavirin, interferon,"/>
 <result pre="to Betacoronavirus which also contains SARS-CoV and Middle East respiratory" exact="syndrome" post="CoV (MERS-CoV). Several drugs, such as ribavirin, interferon, lopinavir-ritonavir,"/>
 <result pre="effects of these compounds on the cytotoxicity, virus yield and" exact="infection" post="rates of 2019-nCoVs. Firstly, the cytotoxicity of the candidate"/>
 <result pre="E6 cells were infected with nCoV-2019BetaCoV/Wuhan/WIV04/20192 at a multiplicity of" exact="infection" post="(MOI) of 0.05 in the presence of varying concentrations"/>
 <result pre="used in the controls. Efficacies were evaluated by quantification of" exact="viral" post="copy numbers in the cell supernatant via quantitative real-time"/>
 <result pre="virus nucleoprotein (NP) expression through immunofluorescence microscopy at 48 h post" exact="infection" post="(p.i.) (cytopathic effect was not obvious at this time"/>
 <result pre="and favipiravir (EC50 = 61.88 μM, CC50 &amp;gt; 400 μM, SI &amp;gt; 6.46) were required to reduce the" exact="viral infection" post="(Fig. 1a and Supplementary information, Fig. S1). However, favipiravir"/>
 <result pre="favipiravir (EC50 = 61.88 μM, CC50 &amp;gt; 400 μM, SI &amp;gt; 6.46) were required to reduce the viral" exact="infection" post="(Fig. 1a and Supplementary information, Fig. S1). However, favipiravir"/>
 <result pre="MERS-CoV, which prevents membrane fusion, was inhibitive against the 2019-nCoV" exact="infection" post="(EC50 = 22.50 μM, CC50 &amp;gt; 100 μM, SI &amp;gt; 4.44). Nitazoxanide, a commercial antiprotozoal agent with"/>
 <result pre="SI &amp;gt; 16.76). Further in vivo evaluation of this drug against 2019-nCoV" exact="infection" post="is recommended. Notably, two compounds remdesivir (EC50 = 0.77 μM; CC50 &amp;gt; 100 μM; SI &amp;gt; 129.87)"/>
 <result pre="(EC50 = 0.77 μM; CC50 &amp;gt; 100 μM; SI &amp;gt; 129.87) and chloroquine (EC50 = 1.13 μM; CC50 &amp;gt; 100 μM, SI &amp;gt; 88.50) potently blocked" exact="virus infection" post="at low-micromolar concentration and showed high SI (Fig. 1a,"/>
 <result pre="CC50 &amp;gt; 100 μM; SI &amp;gt; 129.87) and chloroquine (EC50 = 1.13 μM; CC50 &amp;gt; 100 μM, SI &amp;gt; 88.50) potently blocked virus" exact="infection" post="at low-micromolar concentration and showed high SI (Fig. 1a,"/>
 <result pre="of different doses of the indicated antivirals for 48 h. The" exact="viral" post="yield in the cell supernatant was then quantified by"/>
 <result pre="The experiments were done in triplicates. b Immunofluorescence microscopy of" exact="virus infection" post="upon treatment of remdesivir and chloroquine. Virus infection and"/>
 <result pre="experiments were done in triplicates. b Immunofluorescence microscopy of virus" exact="infection" post="upon treatment of remdesivir and chloroquine. Virus infection and"/>
 <result pre="of virus infection upon treatment of remdesivir and chloroquine. Virus" exact="infection" post="and drug treatment were performed as mentioned above. At"/>
 <result pre="against the NP of a bat SARS-related CoV2 as the" exact="primary" post="antibody and Alexa 488-labeled goat anti-rabbit IgG (1:500; Abcam)"/>
 <result pre="and Alexa 488-labeled goat anti-rabbit IgG (1:500; Abcam) as the" exact="secondary" post="antibody, respectively. The nuclei were stained with Hoechst dye."/>
 <result pre="the drugs were added to the cells for 1 h before" exact="viral" post="attachment, and at 2 h p.i., the virus–drug mixture was"/>
 <result pre="drug against a wide array of RNA viruses (including SARS/MERS-CoV5)" exact="infection" post="in cultured cells, mice and nonhuman primate (NHP) models."/>
 <result pre="infection.6 Remdesivir is an adenosine analogue, which incorporates into nascent" exact="viral" post="RNA chains and results in pre-mature termination.7 Our time-of-addition"/>
 <result pre="data (Supplementary information, Fig. S2) showed that remdesivir also inhibited" exact="virus infection" post="efficiently in a human cell line (human liver cancer"/>
 <result pre="(Supplementary information, Fig. S2) showed that remdesivir also inhibited virus" exact="infection" post="efficiently in a human cell line (human liver cancer"/>
 <result pre="inhibited virus infection efficiently in a human cell line (human" exact="liver cancer" post="Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a"/>
 <result pre="virus infection efficiently in a human cell line (human liver" exact="cancer" post="Huh-7 cells), which is sensitive to 2019-nCoV.2 Chloroquine, a"/>
 <result pre="which is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and" exact="autoimmune" post="disease drug, has recently been reported as a potential"/>
 <result pre="is sensitive to 2019-nCoV.2 Chloroquine, a widely-used anti-malarial and autoimmune" exact="disease" post="drug, has recently been reported as a potential broad-spectrum"/>
 <result pre="a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block" exact="virus infection" post="by increasing endosomal pH required for virus/cell fusion, as"/>
 <result pre="potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus" exact="infection" post="by increasing endosomal pH required for virus/cell fusion, as"/>
 <result pre="at both entry, and at post-entry stages of the 2019-nCoV" exact="infection" post="in Vero E6 cells (Fig. 1c, d). Besides its"/>
 <result pre="can be clinically achievable as demonstrated in the plasma of" exact="rheumatoid arthritis" post="patients who received 500 mg administration.11 Chloroquine is a cheap"/>
 <result pre="be clinically achievable as demonstrated in the plasma of rheumatoid" exact="arthritis" post="patients who received 500 mg administration.11 Chloroquine is a cheap"/>
 <result pre="and chloroquine are highly effective in the control of 2019-nCoV" exact="infection" post="in vitro. Since these compounds have been used in"/>
 <result pre="should be assessed in human patients suffering from the novel" exact="coronavirus disease." post="Supplementary information LINK Supplementary information, Materials and Figures These"/>
</results>
